Patent classifications
C12Y301/01034
LPL/RLP FOR ASSESSMENT OF CARDIOVASCULAR DISEASE RISK
In various embodiments, the application relates to methods for assessment of cardiovascular disease (CVD) risk in a patient comprising comparing pre-heparin LPL (lipoprotein lipase) levels which are associated with protection from CVD to remnant lipoprotein cholesterol (RLP-C) and/or remnant lipoprotein triglyceride content (RLP-Tg).
CHO CELL-DERIVED PROTEIN SECRETORY FACTORS AND EXPRESSION VECTORS COMPRISING THE SAME
The present invention relates to a CHO cell-derived protein secretory factor, an expression cassette in which a nucleic acid sequence encoding the protein secretory factor; and a gene encoding a target protein are operably linked, an expression vector comprising the expression cassette, a transformed cell into which the expression vector is introduced, and a method for producing a target protein using the transformed cell.
Compositions and methods for enzyme immobilization
The present disclosure relates to compositions of immobilized enzymes on the surface of achromosomal and/or anucleate cells and uses thereof. In particular, the present disclosure provides genetically engineered minicells with enzymes self-assembled on their surface. The immobilized enzymes on the surface of achromosomal and/or anucleate minicells, has agricultural, industrial, and environmental applications due to their improved stability durability and, reusability. Also, provided are methods for producing and purifying enzyme-immobilized minicells.
B CELLS FOR IN VIVO DELIVERY OF THERAPEUTIC AGENTS AND DOSAGES THEREOF
The present invention relates to methods for administering autologous and/or allogeneic B cells genetically modified to produce a therapeutic agent, such as a therapeutic protein. Specifically disclosed are methods for administering a single, maximally effective dose of genetically modified B cells and for administering multiple doses of genetically modified B cells. The compositions and methods disclosed herein are useful for the long-term, in vivo delivery of a therapeutic agent.
COMPOSITIONS AND METHODS FOR ENZYME IMMOBILIZATION
The present disclosure relates to compositions of immobilized enzymes on the surface of achromosomal and/or anucleate cells and uses thereof. In particular, the present disclosure provides genetically engineered minicells with enzymes self-assembled on their surface. The immobilized enzymes on the surface of achromosomal and/or anucleate minicells, has agricultural, industrial, and environmental applications due to their improved stability durability and, reusability. Also, provided are methods for producing and purifying enzyme-immobilized minicells.
LPL-GPIHBP1 FUSION POLYPEPTIDES
This disclosure relates to fusion polypeptides comprising lipoprotein lipase (LPL) and glycosylphosphatidylinositol-anchored High Density Lipoprotein-binding protein 1 (GPIHBP1). The disclosure also relates to uses of such fusion polypeptides in treating disease such as familial chylomicronemia syndrome (FCS).
Method for Synthesizing Diglyceride
Disclosed is a method for synthesizing a diglyceride. The diglyceride is obtained by mixing a fatty acid donor with glycerol, partial glyceride lipase, and monoglyceride lipase by adding water, then subjecting the same to an esterification reaction, with a reaction time of 8 to 24 hours, and further separating and purifying the same. In the present invention, monoglyceride lipase is used to promote the reaction efficiency of partial glyceride lipase in the esterification reaction, so as to increase the synthesis rate of diglyceride. Compared with a single enzyme, the synthesis time is shortened by half or more, and 45.50% or more of diglyceride is obtained after the esterification reaction. Since substantially no triglyceride is generated in products, the content of DAG reaches 98% or more after the same has been purified by means of molecular distillation.
RECOMBINANTLY ENGINEERED, LIPASE/ESTERASE-DEFICIENT MAMMALIAN CELL LINES
Mammalian cell lines with reduced expression and/or activity of lipases/esterases, and methods of producing the same are provided. Also provided are compositions comprising polysorbate and recombinant proteins produced in said mammalian cells which have improved polysorbate stability.
MODIFIED MAMMALIAN CELLS
The present disclosure relates to methods, cells, and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interest, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have reduced or eliminated activity, e.g., expression, of certain host cell proteins, e.g., enzymes including, but not limited to, certain lipases, esterases, and/or hydrolases.
COMPOSITIONS AND METHODS FOR ENZYME IMMOBILIZATION
The present disclosure relates to compositions of immobilized enzymes on the surface of achromosomal and/or anucleate cells and uses thereof. In particular, the present disclosure provides genetically engineered minicells with enzymes self-assembled on their surface. The immobilized enzymes on the surface of achromosomal and/or anucleate minicells, has agricultural, industrial, and environmental applications due to their improved stability durability and, reusability. Also, provided are methods for producing and purifying enzyme-immobilized minicells.